Biotech impact fund achieves $265m first close

An 'impact medicine fund' targeting investments in novel treatments for diseases that have until now been underserved has raised $265 million at first close.

To access this article please sign-in below or register for a free one-month trial.

Forgot your password?

To access the premium content on Environmental Finance, you must first sign in to your account

Not registered? Take a free no obligation one-month trial.

Register for a trial